AVITA Medical (FRA:51KA) EBITDA Margin % : -153.71% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. AVITA Medical's EBITDA for the three months ended in Mar. 2024 was €-15.70 Mil. AVITA Medical's Revenue for the three months ended in Mar. 2024 was €10.22 Mil. Therefore, AVITA Medical's EBITDA margin for the quarter that ended in Mar. 2024 was -153.71%.

AVITA Medical EBITDA Margin % Historical Data

The historical data trend for AVITA Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical EBITDA Margin % Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-455.41

-291.15

-88.29

-75.67

-66.89

AVITA Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															-85.79	-86.94	-62.50	-40.46	-153.71

Competitive Comparison of AVITA Medical's EBITDA Margin %

For the Medical Devices subindustry, AVITA Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVITA Medical's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where AVITA Medical's EBITDA Margin % falls into.

AVITA Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

AVITA Medical's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-30.756	/	45.981
	=	-66.89 %

AVITA Medical's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-15.703	/	10.216
	=	-153.71 %

AVITA Medical (FRA:51KA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

AVITA Medical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of AVITA Medical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (FRA:51KA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (FRA:51KA) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

RCEL:USA AVHHL:USA 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.

AVITA Medical (FRA:51KA) Headlines

No Headlines